A Study to Test if TEV-48574 is Effective in Relieving Asthma
Status:
Recruiting
Trial end date:
2022-08-17
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the effect of TEV-48574 compared with
placebo on loss of asthma control (LoAC) in adult patients with T2-low and non-T2 severe
asthma uncontrolled on inhaled corticosteroids plus long-acting beta-agonists (ICS+LABA).
The secondary efficacy objective is to evaluate the effect of TEV-48574 compared with placebo
on a range of clinical measures of asthma control.
The duration of patient participation in the study is planned to be up to approximately 30
weeks.